OMER OMEROS CORP Contract Awards 8-K Filing 2024 - Statistical Analysis Omeros Corporation announced the results of a primary statistical analysis for its monoclonal antibody narsoplimab, targeting a specific condition related to stem cell transplants.Get access to all SEC 8-K filings of the OMEROS CORP